/RGNX
RGNX Stock - REGENXBIO Inc.
Healthcare|BiotechnologyNASDAQ
$14.59+7.99%
+$1.08 (+7.99%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+122.8%upside
Target: $32.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RGNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.44 – $14.74
TARGET (TP)$32.50
STOP LOSS$13.42
RISK/REWARD1:15.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$15.20
52W Low$5.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $83.33M | $90.24M | $112.72M | $470.35M | $154.57M |
| Gross Profit | $49.76M | $53.03M | $58.18M | $418.51M | $118.85M |
| Gross Margin | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% |
| Operating Income | $-233,346,000 | $-268,128,000 | $-262,876,000 | $159.98M | $-119,233,000 |
| Net Income | $-227,102,000 | $-263,494,000 | $-280,321,000 | $127.84M | $-111,250,000 |
| Net Margin | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% |
| EPS | $-4.59 | $-6.02 | $-6.50 | $3.01 | $-2.98 |
Company Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
91%
Hold / Neutral
1
9%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish1 Neutral/Bearish
Price Targets
$34
Average Target
↑ 134.2% Upside
Now
$14
Low
$34
Average
$61
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 11th 2025 | Goldman | Downgrade | Neutral | $14← $38 |
| February 7th 2025 | Raymond James | Resumed | Outperform | $27 |
| November 15th 2024 | Morgan Stanley | Resumed | Overweight | $22 |
| October 10th 2024 | Raymond James | Resumed | Outperform | $18 |
| June 7th 2024 | Goldman | Initiation | Buy | $38 |
| March 11th 2024 | H.C. Wainwright | Initiation | Buy | $36 |
| March 8th 2024 | RBC Capital Mkts | Upgrade | Outperform | $35← $20 |
| March 6th 2024 | Leerink Partners | Upgrade | Outperform | $37 |
| February 21st 2024 | Raymond James | Resumed | Outperform | $45 |
| November 1st 2023 | Stifel | Initiation | Buy | $35 |
| June 2nd 2023 | Robert W. Baird | Initiation | Outperform | $42 |
| June 23rd 2022 | Berenberg | Initiation | Buy | $61 |
Earnings History & Surprises
RGNXBeat Rate
33%
Last 18 quarters
Avg Surprise
-9.8%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-1.20
Q4 2025
EPS Surprise History
Q1 24
-12.6%
$-1.43vs$-1.27
Q2 24
-7.8%
$-1.38vs$-1.28
Q3 24
+18.6%
$-1.05vs$-1.29
Q4 24
-0.9%
$-1.17vs$-1.16
Q1 25
+20.5%
$-1.01vs$-1.27
Q2 25
-70.7%
$0.12vs$0.41
Q3 25
-22.1%
$-1.38vs$-1.13
Q4 25
+13.0%
$-1.20vs$-1.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-1.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.38 | $-1.20 | +13.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.13 | $-1.38 | -22.1% | ✗ MISS |
Q2 2025 | May 12, 2025 | $0.41 | $0.12 | -70.7% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-1.27 | $-1.01 | +20.5% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.16 | $-1.17 | -0.9% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-1.29 | $-1.05 | +18.6% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.28 | $-1.38 | -7.8% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-1.27 | $-1.43 | -12.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-1.44 | $-1.41 | +2.1% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-1.26 | $-1.66 | -31.7% | ✗ MISS |
Q2 2023 | May 3, 2023 | $-1.52 | $-1.53 | -0.7% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-1.48 | $-1.38 | +6.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.55 | $-1.75 | -12.9% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-1.44 | $-1.58 | -9.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-1.29 | $-1.62 | -25.6% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $4.71 | $6.67 | +41.6% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.87 | $-1.37 | -57.5% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-1.08 | $-1.36 | -25.9% | ✗ MISS |
Latest News
Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $20
📈 PositiveBenzinga•Dec 15, 2025, 08:50 PM
REGENXBIO Files For Mixed Shelf Of Up To $300M
➖ NeutralBenzinga•Nov 26, 2025, 09:18 PM
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
📈 PositiveBenzinga•Nov 20, 2025, 12:30 PM
RBC Capital Maintains Outperform on Regenxbio, Raises Price Target to $19
📈 PositiveBenzinga•Nov 7, 2025, 07:23 PM
Regenxbio Q3 EPS $(1.20) Beats $(1.33) Estimate, Sales $29.733M Beat $24.125M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:09 PM
REGENXBIO Completes Enrollment In AFFINITY DUCHENNE Pivotal Trial Of RGX-202; Initiates Commercial Production Duchenne Gene Therapy Program
📈 PositiveBenzinga•Oct 30, 2025, 11:13 AM
REGENXBIO to Present Data on Sura-vec for Diabetic Retinopathy at American Academy of Ophthalmology
➖ NeutralBenzinga•Oct 9, 2025, 11:25 AM
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
📈 PositiveBenzinga•Oct 7, 2025, 10:15 AM
REGENXBIO Completes Enrollment In ATMOSPHERE And ASCENT Pivotal Studies Evaluating Surabgene Lomparvovec In Wet AMD Using Subretinal Delivery
📈 PositiveBenzinga•Oct 6, 2025, 11:10 AM•Also:
REGENXBIO To Present RGX-202 Phase I/II Functional Data At WMS 2025; Highlights NSAA Gains, Favorable Safety Profile Vs. Natural History Controls
📈 PositiveBenzinga•Sep 29, 2025, 11:18 AM
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 11:37 AM
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 10:59 AM
REGENXBIO Announces Data From Phase I/II/III CAMPSIITE Trial Of Clemidsogene Lanparvovec For Treatment Of Patients With Mucopolysaccharidosis Type II At ICIEM 2025
➖ NeutralBenzinga•Sep 5, 2025, 11:08 AM
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 11:00 AM
REGENXBIO Reveals FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II; PDUFA Date Extended To February 8, 2026
➖ NeutralBenzinga•Aug 18, 2025, 09:04 PM
REGENXBIO announces royalty monetization agreement for up to $250M
📈 PositiveSeeking Alpha•May 19, 2025, 08:14 PM
Frequently Asked Questions about RGNX
What is RGNX's current stock price?
REGENXBIO Inc. (RGNX) is currently trading at $14.59 per share. The stock has moved +7.99% today.
What is the analyst price target for RGNX?
The average analyst price target for RGNX is $32.50, based on 1 analyst.
What sector is REGENXBIO Inc. in?
REGENXBIO Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RGNX's market cap?
REGENXBIO Inc. has a market capitalization of $0.74 billion, making it a small-cap company.
Does RGNX pay dividends?
No, REGENXBIO Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to RGNX for comparison